Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) ...

Vanda Pharmaceuticals said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health ...

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...

The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked ...

FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...

The FDA has approved tradipitant (Nereus), an oral NK-1 receptor antagonist, for preventing motion-induced vomiting in adults ...

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment ...

Vanda Pharmaceuticals has received FDA approval for Nereus (tradipitant), an oral NK-1 receptor antagonist developed to prevent motion-induced vomiting. The approval makes Nereus the first new ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA ...

Vanda Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its drug tradipitant, ...

The FDA decision was based on results from three late-stage clinical studies, including two Phase 3 trials conducted in ...

The end-of-year holidays are often synonymous with long journeys and motion sickness, which can cause nausea and dizziness.